Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab. Clinical data from a phase 1 trial with lumiliximab demonstrated an acceptable toxicity profile in patients with relapsed or refractory chronic lympho...

Full description

Saved in:
Bibliographic Details
Main Authors: Byrd, John C., Kipps, Thomas J., Flinn, Ian W., Castro, Januaro, Lin, Thomas S., Wierda, William, Heerema, Nyla, Woodworth, James, Hughes, Steve, Tangri, Shabnam, Harris, Sarah, Wynne, Dee, Molina, Arturo, Leigh, Bryan, O'Brien, Susan
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2010
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2810983/
https://ncbi.nlm.nih.gov/pubmed/19843887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-08-237727
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items